Immunomodulators acting as antagonists of PD-1
US11066445B2 · kind B2 · utility
2Cited by
17References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2018 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Jun 21, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.